potent therapeutic applied spliceswitch oligonucleotid sso model premrna splice increasingly revid number disease howe primary drawback approach poor cell vivo oligonucleotid uptake efficacy biology active significantly enhance use synthetic concur cation center peptide cpp studi date focus delivery single sso cpp describe concur two phosphorodiamid morpholino pm sultan target spear gene exon dmy gene acre mouse model duchess muscular dystrophy concur pm carry amid bond one case trial linkage click chemistry active bispecif cpppmo demons compare skip level target compare individual cpppmo concur culture mdy thu differ target sequence biology effect potent suitable future exploit 